Top Story

Intercept files new drug application with FDA for obeticholic acid

June 30, 2015

Intercept Pharmaceuticals, Inc. has submitted a new drug application to the FDA for obeticholic acid to be used in combination with ursodeoxycholic acid to treat primary biliary cirrhosis, according to a press release.

Obeticholic acid (OCA) will be intended for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who did not respond to previous UDCA therapy or as monotherapy in adults unable to tolerate UDCA, according to the release.

Medicare fraud takedown: A closer look Health Care Legislative and Regulatory Update

Medicare fraud takedown: A closer look

June 30, 2015
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of…
In the Journals

Low vitamin D may lead to poor outcomes, infections in patients with cirrhosis

June 30, 2015
Low 25-hydroxyvitamin D3 levels were found to be associated with advanced liver disease, poor outcomes and infectious complications in patients with cirrhosis…
Breaking News

FDA is sued by public health groups over Sovaldi, Harvoni

June 30, 2015
The Global Health Justice Partnership at Yale University and Treatment Action Group have filed a lawsuit against the FDA in an effort to gain access to clinical trial…
Arthur Kim In the Journals

Study suggests less than 1% of acute HCV cases reported to the CDC

June 29, 2015
In a new study published in Annals of Internal Medicine, researchers in Massachusetts found that less than 1% of acute cases of hepatitis C virus infection over the…
More News Headlines »
CME
j64a_activity

CRITICAL ISSUES IN HBV: Considerations in Optimizing HBV Treatment

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

Hepatitis B virus (HBV) infection is a global epidemic with a worldwide burden. Physicians must address the importance…
More »
Meeting News Coverage Video

VIDEO: NAFLD patients need a healthy lifestyle

May 13, 2015
VIENNA — In a video perspective from the 2015 International Liver Congress, Howard Monsour Jr., MD, chief of…
More »
CME
Pediatric Fatty Liver

Case Challenges in Pediatric Fatty Liver: What to Look For and When to Refer

This activity is supported by an educational grant from Synageva BioPharma Corp.

Non-alcoholic fatty liver disease (NAFLD) is characterized by excess fat deposition in the liver due to causes other…
More »
morganatic-roan